CN Group Announces: Acclaim Biotechnology To Present Investment Opportunity At Southwest Bio Venture 
10/19/2005 5:09:27 PM

AUSTIN, Texas, Dec. 8 /PRNewswire/ -- CN Group and Texas Healthcare and Bioscience Institute today announced that Acclaim Biotechnology, a Houston- based emerging life sciences company developing therapeutics for the treatment of liver diseases and cancer, will unveil its investment opportunity at the 2003 Southwest Bio Venture Conference & Symposium being held in Houston December 9th and 10th. Acclaim Biotechnology is working to commercialize novel therapeutic products developed by researches at UT M.D. Anderson Cancer Center (MDACC).

There are approximately 17,000 new cases of liver cancer found in the United States annually, representing medical cost over $3.5 billion a year. World-wide, 350 million people are affected by liver diseases. Research indicates that Acclaim Biotechnology's therapy is effective, non-toxic to normal cells, and has liver targeting specificity, which is superior to the conventional systemic and infusion therapy.

The company's management team includes: Prof. M.T. Kuo, a major contributor to the field of drug resistance, gene amplification and liver cancer; John Y Chan Ph.D., president, seasoned laboratory administrator and former faculty of MDACC for 20 years; and, Cheng Peng Ph.D., a former project leader at Tanox Inc. for over 10 years. The intellectual property assets include, one granted and one pending patent.

About Acclaim Biotechnology

Acclaim Biotechnology's mission is to develop and market products, therapeutics and strategies based on the receptor-mediated delivery technology. The Company will use its platform technologies to develop therapeutics targeted to the liver. The lead product (CD-CS) is a patented fusion protein with a drug-metabolizing enzyme (CD) and a liver-targeting protein (CS) from the malarial parasite. The CS protein targets the surface receptors of the liver cells, while the CD enzyme converts a nontoxic prodrug to the toxic metabolite. This regimen is preferentially toxic to the proliferating tumor cells, and the non-tumor liver tissues and other organs are essentially not affected. Research conducted indicates that this approach is specific, efficiency and safe. Therefore, this product is particularly applicable for improving chemotherapy of liver cancer and liver metastasis, which affect tens of thousands of patients worldwide. Venture capitals and partners are welcome to join in developing and commercializing this novel technology. For more information, please visit the company web site at

About CN Group

CN Group helps build growth companies through three business efforts. CN Events produces the leading Venture Capital, Private Equity and Angel Investor gatherings in the Southwest. CN Management Services assists companies in building their management team and Board and Advisory Boards. Capital Network Securities, a NASD-approved investment bank, provides merger and acquisition advisory services, and capital-raising services for select growth companies. For more information please visit

About Texas Healthcare and Bioscience Institute

The Texas Healthcare and Bioscience Institute (THBI) is a public policy research organization, whose members consist of biotechnology, medical device, and pharmaceutical companies, academic and private research institutions, chambers of commerce, and local and regional economic development foundations.

The mission of THBI is to research, develop and advocate policies that promote life science innovation in Texas. For more information, visit

Media Contact: Patti D. Hill BlabberMouth Public Relations (512) 528 - 0201

CN Group

CONTACT: Patti D. Hill of BlabberMouth Public Relations,+1-512-528-0201,